RXi Pharmaceuticals and miRagen Therapeutics entered into a collaboration to evaluate RXi’s rxRNA™ technology against specific miRNA targets of interest to miRagen in the cardiac and neuromuscular disease areas. Each party will contribute its technology and resources to the collaboration to generate novel miRNA compounds.

RXi says that its version of RNAi compounds, developed on the rxRNA platform, provide an alternative to siRNAs. These include rxRNAori™, rxRNAsolo™, and sd-rxRNA™ (self-delivering RNA), which are distinct from classic siRNAs.